ABSTRACT
INTRODUCTION: cancer and its treatments have been associated with poor nutritional status in children and adolescents. OBJECTIVE: to establish the nutritional risk of pediatric patients and the degree of food and nutritional insecurity in the homes of children and adolescents with cancer who have been hospitalized in a high complexity pediatric oncology center. METHODS: a prospective observational study conducted at the Fundación Hospital Pediátrico la Misericordia - HOMI. It included a sample of 41 children and adolescents aged 0 to 17 years and 11 months with a diagnosis of childhood cancer during the study period. The participants recruited during hospitalization had the application of the SCAN nutritional screening tool for childhood cancer, Spanish version, validated in HOMI and the Latin American and Caribbean Scale of Food and Nutritional Security - ELCSA, adapted and validated in Colombia. RESULTS: 76 % (n = 31) of the patients were classified as "At risk of malnutrition" using the SCAN-SP nutritional screening tool. It was observed that 56 % of all households had a proportion of food insecurity, of which the classification of food (in)security was mild in 29 %, moderate in 20 % and severe in 7 % of households with children under 18 years of age. CONCLUSION: in the framework of the nutritional care process, it is important to take into account factors that include a complete nutritional risk assessment and evaluation that includes the measurement of food security.
ABSTRACT
Introduction: Introduction: the prevalence of undernutrition in the pediatric cancer population can vary considerably, an element that significantly influences the clinical outcome of patients. However, this is a potentially modifiable prognostic factor, which requires timely identification of nutritional risk to guide the nutritional care process. Objectives: to evaluate the operational performance of the Spanish version of the nutritional screening tool for childhood cancer (SCAN) in the context of the validation process of this instrument in a high-complexity hospital in the city of Bogotá, Colombia. Methods: the methodological design for the validation of a diagnostic scale was followed. The final sample consisted of 96 patients between 0 and 17 years with cancer and hospitalized at the Children's Cancer Center of the HOMI Foundation in Bogota. The SCAN-SP was applied to each patient and a complete nutritional assessment (CNA) was performed as a gold standard to determine nutritional status. Results: 82.3 % (n = 79) of patients were classified "at risk of malnutrition" by SCAN-SP and 69.8 % (n = 67) of the total sample had undernutrition. The evaluation of the operative performance of SCAN-SP against CNA showed excellent results: sensitivity of 100 %, specificity of 59 %, PPV of 85 %, NPV of 100 %, positive likelihood ratio of 2.4, and negative likelihood ratio of 0. Conclusion: the SCAN-SP scale performs well as a nutritional screening tool in pediatric cancer patients, so its use in clinical practice is recommended.
Introducción: Introducción: la prevalencia de la desnutrición en la población con cáncer infantil puede variar notablemente, elemento que influye de manera significativa en el desenlace clínico de los pacientes. No obstante, este es un factor pronóstico potencialmente modificable y para ello se requiere una identificación del riesgo nutricional oportuna que oriente el proceso de cuidado nutricional. Objetivo: evaluar el rendimiento operativo de la versión en español de la escala de tamización nutricional para el cáncer infantil (SCAN-SP) en el marco del proceso de validación del instrumento en un hospital de alta complejidad en la ciudad de Bogotá, Colombia. Métodos: se siguió el diseño metodológico para la validación de una escala diagnóstica. La muestra final fue de 96 pacientes entre los 0 y 17 años con cáncer y hospitalizados en el Centro de Cáncer Infantil de la Fundación HOMI en Bogotá. A cada paciente se le aplicó la SCAN-SP y también se le realizó una valoración nutricional completa (VNC) tomada como patrón de referencia para conocer su estado nutricional. Resultados: el 82,3 % (n = 79) de los pacientes fueron clasificados como "con riesgo de desnutrición" por la SCAN-SP y el 69,8 % (n = 67) del total de la muestra estaban realmente desnutridos. La evaluación del rendimiento operativo de la SCAN-SP contra la VNC mostro excelentes resultados: sensibilidad del 100 %, especificidad del 59 %, VPP del 85 %, VPN del 100 %, RVP de 2,4 y una RVN de 0. Conclusión: la escala SCAN-SP tiene un buen comportamiento como herramienta de tamización nutricional en el paciente pediátrico con cáncer, por lo que se recomienda su uso en la práctica clínica.
Subject(s)
Malnutrition , Neoplasms , Humans , Child , Nutritional Status , Nutrition Assessment , Neoplasms/complications , Early Detection of Cancer , Malnutrition/diagnosis , Malnutrition/epidemiologyABSTRACT
Background: Children with cancer are at risk of critical disease and mortality from COVID-19 infection. In this study, we describe the clinical characteristics of pediatric patients with cancer and COVID-19 from multiple Latin American centers and risk factors associated with mortality in this population. Methods: This study is a multicenter, prospective cohort study conducted at 12 hospitals from 6 Latin American countries (Argentina, Bolivia, Colombia, Ecuador, Honduras and Peru) from April to November 2021. Patients younger than 14 years of age that had an oncological diagnosis and COVID-19 or multisystemic inflammatory syndrome in children (MIS-C) who were treated in the inpatient setting were included. The primary exposure was the diagnosis and treatment status, and the primary outcome was mortality. We defined "new diagnosis" as patients with no previous diagnosis of cancer, "established diagnosis" as patients with cancer and ongoing treatment and "relapse" as patients with cancer and ongoing treatment that had a prior cancer-free period. A frequentist analysis was performed including a multivariate logistic regression for mortality. Results: Two hundred and ten patients were included in the study; 30 (14%) died during the study period and 67% of patients who died were admitted to critical care. Demographics were similar in survivors and non-survivors. Patients with low weight for age (<-2SD) had higher mortality (28 vs. 3%, p = 0.019). There was statistically significant difference of mortality between patients with new diagnosis (36.7%), established diagnosis (1.4%) and relapse (60%), (p <0.001). Most patients had hematological cancers (69%) and they had higher mortality (18%) compared to solid tumors (6%, p= 0.032). Patients with concomitant bacterial infections had higher mortality (40%, p = 0.001). MIS-C, respiratory distress, cardiovascular symptoms, altered mental status and acute kidney injury on admission were associated with higher mortality. Acidosis, hypoxemia, lymphocytosis, severe neutropenia, anemia and thrombocytopenia on admission were also associated with mortality. A multivariate logistic regression showed risk factors associated with mortality: concomitant bacterial infection OR 3 95%CI (1.1-8.5), respiratory symptoms OR 5.7 95%CI (1.7-19.4), cardiovascular OR 5.2 95%CI (1.2-14.2), new cancer diagnosis OR 12 95%CI (1.3-102) and relapse OR 25 95%CI (2.9-214). Conclusion: Our study shows that pediatric patients with new onset diagnosis of cancer and patients with relapse have higher odds of all-cause mortality in the setting of COVID-19. This information would help develop an early identification of patients with cancer and COVID-19 with higher risk of mortality.
ABSTRACT
Introducción: la prevalencia de la desnutrición en la población con cáncer infantil puede variar notablemente, elemento que influye de manera significativa en el desenlace clínico de los pacientes. No obstante, este es un factor pronóstico potencialmente modificable y para ello se requiere una identificación del riesgo nutricional oportuna que oriente el proceso de cuidado nutricional. Objetivo: evaluar el rendimiento operativo de la versión en español de la escala de tamización nutricional para el cáncer infantil (SCAN-SP) en el marco del proceso de validación del instrumento en un hospital de alta complejidad en la ciudad de Bogotá, Colombia. Métodos: se siguió el diseño metodológico para la validación de una escala diagnóstica. La muestra final fue de 96 pacientes entre los 0 y 17 años con cáncer y hospitalizados en el Centro de Cáncer Infantil de la Fundación HOMI en Bogotá. A cada paciente se le aplicó la SCAN-SP y también se le realizó una valoración nutricional completa (VNC) tomada como patrón de referencia para conocer su estado nutricional. Resultados: el 82,3 % (n = 79) de los pacientes fueron clasificados como con riesgo de desnutrición por la SCAN-SP y el 69,8 % (n = 67) del total de la muestra estaban realmente desnutridos. La evaluación del rendimiento operativo de la SCAN-SP contra la VNC mostro excelentes resultados: sensibilidad del 100 %, especificidad del 59 %, VPP del 85 %, VPN del 100 %, RVP de 2,4 y una RVN de 0. Conclusión: la escala SCAN-SP tiene un buen comportamiento como herramienta de tamización nutricional en el paciente pediátrico con cáncer, por lo que se recomienda su uso en la práctica clínica. (AU)
Introduction: the prevalence of undernutrition in the pediatric cancer population can vary considerably, an element that significantly influences the clinical outcome of patients. However, this is a potentially modifiable prognostic factor, which requires timely identification of nutritional risk to guide the nutritional care process. Objectives: to evaluate the operational performance of the Spanish version of the nutritional screening tool for childhood cancer (SCAN) in the context of the validation process of this instrument in a high-complexity hospital in the city of Bogotá, Colombia. Methods: the methodological design for the validation of a diagnostic scale was followed. The final sample consisted of 96 patients between 0 and 17 years with cancer and hospitalized at the Childrens Cancer Center of the HOMI Foundation in Bogota. The SCAN-SP was applied to each patient and a complete nutritional assessment (CNA) was performed as a gold standard to determine nutritional status. Results: 82.3 % (n = 79) of patients were classified at risk of malnutrition by SCAN-SP and 69.8 % (n = 67) of the total sample had undernutrition. The evaluation of the operative performance of SCAN-SP against CNA showed excellent results: sensitivity of 100 %, specificity of 59 %, PPV of 85 %, NPV of 100 %, positive likelihood ratio of 2.4, and negative likelihood ratio of 0.Conclusion: the SCAN-SP scale performs well as a nutritional screening tool in pediatric cancer patients, so its use in clinical practice is recommended. (AU)
Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Malnutrition/epidemiology , Malnutrition/complications , Neoplasms/epidemiology , Nutritional Status , Prevalence , Nutrition Assessment , ColombiaABSTRACT
Abstract Introduction: In the United States, between 4 and 8% of children with acute myeloid leukemia have acute promyelocytic leukemia (APL), but a higher incidence of this malignancy has been reported in Latin America (20%-28%). The implementation of the PETHEMA LPA 99 protocol, designed for the treatment of APL in adults, has shown an overall survival (OS) >80%. Objective: To describe the results obtained after the implementation of the PETHEMA LPA 99 protocol to treat children with APL at the Fundación Hospital Pediátrico La Misericordia in Bogotá, D.C., Colombia. Materials and methods: Descriptive and retrospective cohort study. The medical records of 30 pediatric patients (<18 years) with APL, who were treated using the PETHEMA LPA 99 protocol between January 2005 and December 2012, were reviewed. Data on the following variables were obtained: early death, death during induction therapy, OS, event-free survival (EFS), and relapse. Results: The male sex was predominant (60%) among the 30 patients included in the study. Regarding risk classification, 13 (43%) were classified as high-risk patients, 12 (40%) as medium-risk, and 5 (17%) as low-risk. Seven individuals died: 2 before receiving cancer treatment, 2 during induction therapy, and 3 after relapse. Relapse was reported in 5 patients. There were no deaths during the consolidation or maintenance phases. OS was 75.4% (95%CI: 55.1-87.5) and EFS was 64.3% (95%CI: 40-80.5). Moreover, OS at 11 years was 80%, 91.7%, and 59.2% for low-risk, intermediate-risk, and high-risk patients, respectively. The median follow-up time was 6.35 years (0-11.43 years). Conclusions: In general, the implementation of the PETHEMA LPA 99 protocol to treat APL in the study population showed very satisfactory results. Therefore, its use in pediatric population is recommended, taking into account the adjustments described in the protocol regarding the characteristics of this age group.
Resumen Introducción. En Estados Unidos de América, entre 4 y 8% de niños con leucemias mieloides agudas tienen leucemia promielocítica aguda (LPA), mientras que en Latinoamérica se ha descrito una mayor incidencia de esta neoplasia (20-28%). La implementación del protocolo PETHEMA LPA 99, diseñado para el tratamiento de LPA en adultos, ha mostrado una supervivencia global (SG) >80%. Objetivo. Describir los resultados de la aplicación del protocolo PETHEMA LPA 99 en el tratamiento de niños con LPA en la Fundación Hospital Pediátrico la Misericordia, en Bogotá D.C., Colombia. Materiales y métodos. Estudio de cohorte descriptivo y retrospectivo. Se revisaron las historias clínicas de 30 pacientes pediátricos (<18 años) con LPA que recibieron tratamiento mediante el protocolo PETHEMA LPA 99 entre enero de 2005 y diciembre de 2012. Se obtuvieron datos sobre las siguientes variables: muerte temprana, muerte en terapia de inducción, SG, supervivencia libre de evento (SLE) y recaída. Resultados. De los 30 pacientes, la mayoría eran de sexo masculino (60%). Respecto a la clasificación de riesgo, 13 (43%) fueron clasificados como pacientes de riesgo alto; 12 (40%), de riesgo intermedio, y 5 (17%), de riesgo bajo. 7 individuos murieron: 2 antes del tratamiento oncológico, 2 durante la terapia de inducción y 3 luego de presentar recaída. Se reportó recaída en 5 pacientes. No hubo muertes durante las fases de consolidación o de mantenimiento. La SG fue de 75.4% (IC95%: 55.1-87.5) y la SLE fue de 64.3% (IC95%: 40-80.5). La SG a 11 años fue de 80%, 91.7% y 59.2% para los pacientes de riesgo bajo, riesgo intermedio y riesgo alto, respectivamente. La mediana de seguimiento fue 6.35 años (0-11.43 años). Conclusiones. En general, la implementación del protocolo PETHEMA LPA 99 en el tratamiento de la LPA en la población de estudio mostró resultados muy satisfactorios, por lo que se recomienda su uso en población pediátrica, teniendo en cuenta los ajustes recomendados por el protocolo en relación con las características de este grupo etario.
ABSTRACT
RESUMEN Introducción: la leucemia aguda es la neoplasia más común en niños, constituye aproximadamente el 25 % de todos los tumores en la infancia. En Colombia la proporción de curación, alrededor del 50 %, es inferior a lo informado en países desarrollados. Objetivo: el objetivo principal es determinar la supervivencia global y libre de eventos, la proporción de abandono y recaída de los niños con el diagnóstico de leucemia linfoide aguda tratados con el Protocolo ACHOP 2006. Materiales y métodos: estudio descriptivo de tipo cohorte de 183 pacientes menores de 18 años, con el diagnóstico confirmado de leucemia linfoide aguda, que recibieron tratamiento en la Fundación HOMI desde el 2007 hasta el 2012. Los análisis de supervivencia se obtuvieron con curvas de Kaplan-Meier. Resultados: se analizó la supervivencia global a 2, 3 y 5 años con resultados de 89 %, 87,3 % y 74,7 % (IC 95 % 67-80,9), respectivamente. A los 5 años la supervivencia para el grupo de riesgo estándar fue de 78,6 % (IC 95 % 68,3 - 85,1) y para el de riesgo alto 61,9 % (IC 95 % 50,7- 73). La supervivencia libre de evento, al considerar el abandono y traslado a otra institución como evento, fue de 56,3 % (IC 95 % 45,5-65,8) a los 5 años. La mortalidad en inducción fue de 3,8 %, la mortalidad relacionada con el tratamiento fue 3,4 %. Treinta y dos pacientes (17 %) recayeron, el abandono fue de 16,4 % y los traslados de 10,4 %. La principal complicación del tratamiento fueron las infecciones. Conclusiones: la supervivencia global es aceptable para un país de recursos limitados. Los eventos de abandono y traslado son muy altos. Deben aunarse esfuerzos para disminuir estas situaciones que empeoran el pronóstico de la enfermedad.
SUMMARY Introduction: Acute leukemia is the most common neoplasm in children, accounting for approximately 25% of all tumors in childhood. In Colombia the cure proportion, around 50%, are lower than reported in developed countries. Objective: The main objective is to determine the global and event-free survival of children with diagnosis of lymphoblastic leukemia, all treated with the ACHOP Protocol 2006, from 2007 to 2012. The secondary objectives are to describe mortality, abandonment, relapse and major complications related to treatment. Material and methods: A descriptive cohort study of 183 patients under 18 years of age, with a confirmed diagnosis of acute lymphoblastic leukemia, who were treated at the Foundation of the Misericordia (HOMI) from 2007 to 2012, was performed. The survival dates were obtained by analysis with Kaplan-Meier curves. Results: We analyzed overall survival at 2, 3 and 5 years with results of 89%, 87.3% and 74.7 % (95% CI 67 - 80.9) respectively. At 5 years survival for the standard risk group was 78.6 % (95 % CI 68.3-85.1) and 61.9 % (95 % CI 50.7-73) for the high risk group. The event-free survival, considering the abandonment and transfer to another institution as an event, was 56.3 % (95% CI 45.5 - 65.8) at 5 years. Mortality in induction was 3.8 %, mortality related to treatment was 3.4 %, 32 patients (17 %) relapsed, abandonment was 16.4 % and transfers 10.4 %. The main complication of the treatment was infections. Conclusions: Overall survival is acceptable for a country with limited resources, the events of abandonment and transfers are very high. Efforts should be made to reduce these situations that worsen the prognosis of the disease.
Subject(s)
Precursor Cell Lymphoblastic Leukemia-Lymphoma , Cohort Studies , Minors , HospitalsABSTRACT
Introduction: Transfusion therapy is probably one of the most widely used therapies with poor supporting evidence, despite the long years of practical clinical use. Objective: To adapt the evidence-based recommendations on the use of blood products to the Colombian setting: red blood cells, platelets, cryoprecipitates and irradiated blood products in cancer patients under 18 years of age. Methods: Standard methodologies were followed in the development of recommendations. First, the clinical questions were addressed, and the evidence-based clinical practice guidelines were identified, graded and selected to answer the clinical questions. A systematic methodology was used to qualify, obtain and describe the relevant information to generate recommendations based on the SIGN system. The results were then presented and discussed in a group of experts to establish the practical value of the evidence and to adapt the recommendations to the Colombian environment. Results: Out of 107,441 preliminary titles, 56 studies were analyzed, and from them 3 clinical practice guidelines and 4 Cochrane systematic reviews were selected. This evidence was evaluated using AGREE II and AMSTAR. Red blood cells transfusion support is recommended using the restrictive strategy. Prophylactic platelet transfusion is the recommended indication. Cryoprecipitate is recommended when fibrinogen levels fall below 100mg/dL, and indications on irradiated blood products were established. Conclusion: This paper is an evidence-base approach on the recommendations for transfusion therapy in children with cancer.
Introducción: La terapia transfusional es quizá una de los tratamientos de mayor uso sin buen respaldo de evidencia, a pesar de muchos años de uso en la práctica clínica. Objetiuo:Adaptar recomendaciones basadas en evidencia al contexto colombiano sobre el uso de hemocomponentes: glóbulos rojos, plaquetas, crioprecipitados y hemocomponentes irradiados en el paciente oncológico menor de 18 años. Métodos: Se utilizaron metodologías estándares para el desarrollo de las recomendaciones. Primero se formularon las preguntas clínicas, se identificaron, calificaron y seleccionaron las guías de práctica clínica basadas en la evidencia que respondían las preguntas clínicas, utilizando una metodología sistemática se realizó la calificación, extracción y descripción de los aspectos relevantes para generar recomendaciones usando el sistema SIGN, luego se realizaron exposición y discusión de los resultados obtenidos con un grupo de expertos para seleccionar la utilidad de la evidencia y adaptar las recomendaciones al contexto colombiano. Resultados: De 107.441 títulos preliminares, se analizaron 56 estudios, y de estos se escogieron 3 guías de práctica clínica y 4 revisiones sistemáticas Cochrane. Se evaluó esta evidencia con AGREE II y AMSTAR. Se recomienda soporte transfusional de glóbulos rojos usando la estrategia restrictiva, la estrategia transfusional profiláctica de plaquetas es la indicación recomendada. El valor de fibrinógeno menor de 100mg/dl es el recomendado para utilizar crioprecipitados y se determinaron las indicaciones sobre hemocomponentes irradiados. Conclusiones Este trabajo representa un enfoque basado en la evidencia sobre las recomendaciones de terapia transfusional para niños con cáncer.